Investigation of the Low-Dose Response in the In Vivo Induction of Micronuclei and Adducts by Acrylamide

• Published in: Toxicological sciences Vol. 107; no. 1; pp. 247 - 257
• Main Authors: Zeiger, Errol, Recio, Leslie, Fennell, Timothy R., Haseman, Joseph K., Snyder, Rodney W., Friedman, Marvin
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01-01-2009
• Subjects: acrylamide; Acrylamide - administration & dosage; Acrylamide - toxicity; Analysis of Variance; Animals; Body Weight; bone marrow; Bone Marrow - drug effects; Chromosome Aberrations - drug effects; DNA adducts; DNA Adducts - metabolism; Dose-Response Relationship, Drug; Epoxy Compounds - metabolism; Erythrocytes - drug effects; glycidamide; hemoglobin adducts; Hemoglobins - metabolism; Liver - chemistry; Mice; Mice, Transgenic; Micronuclei, Chromosome-Defective - drug effects; micronucleus test; Micronucleus Tests - methods; mouse; Regression Analysis; Reticulocytes - drug effects; threshold; mouse; acrylamide; micronucleus test; hemoglobin adducts; threshold; DNA adducts; glycidamide; bone marrow
• ISSN: 1096-6080; 1096-0929
• DOI: 10.1093/toxsci/kfn214

Acrylamide is an industrial chemical used in polymer manufacture. It is also formed in foods processed at high temperatures. It induces chromosome aberrations and micronuclei (MN) in somatic cells of mice, but not rats, and mutations in transgenic mice. This study evaluated the low-dose MN response in mouse bone marrow and the shape of the dose-response curve. Mice were treated orally with acrylamide for 28 days using logarithmically spaced doses from 0.125 to 24 mg/kg/day, and MN were assessed in peripheral blood reticulocytes (RETs) and erythrocytes by flow cytometry. Liver glycidamide DNA adducts and acrylamide and glycidamide N-terminal valine hemoglobin adducts were also determined. Acrylamide produced a weak MN response, with statistical significance at 6.0 mg/kg/day, or greater, in MN-RETs and at 4.0 mg/kg/day or greater in MN normochromatic erythrocytes (NCEs). The MN responses at the lower doses were indistinguishable from the concurrent and historical controls. The adducts increased at a much different rate than the MN. When the MN-NCE values were compared to administered dose, the response was consistent with a linear model. However, when hemoglobin or DNA adducts were used as the dose metric, the response was significantly nonlinear, and models that assumed a threshold dose of 1 or 2 mg/kg/day provided a better fit than a linear model. The MN-RET dose-response had greater variability than the MN-NCE response and was consistent with linearity and with a threshold at 1 or 2 mg/kg/day, regardless of the dose metric. These data suggest a threshold for acrylamide in the MN test.